Future directions for research on Silybum marianum for cancer patients (Q36840447)

16 August 2017

1 reference

title

Future directions for research on Silybum marianum for cancer patients (English)

1 reference

16 August 2017

Silybum marianum

1 reference

Stephen M Sagar

1

1 reference

16 August 2017

1 June 2007

1 reference

Integrative Cancer Therapies

16 August 2017

1 reference

16 August 2017

6

1 reference

16 August 2017

2

1 reference

16 August 2017

166-173

1 reference

Development and validation of analytical methods for dietary supplements.

16 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Dietary supplement Standard Reference Materials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Saw palmetto for benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Applications of LC-MS in the study of the uptake, distribution, metabolism and excretion of bioactive polyphenols from dietary supplements

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Natural health products and drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Chemical and biological characterization and clinical evaluation of botanical dietary supplements: a phase I red clover extract as a model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Natural flavonoids targeting deregulated cell cycle progression in cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Primary cultures of human hepatocytes as a tool in cytotoxicity studies: cell protection against model toxins by flavonolignans obtained from Silybum marianum

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Flavonoid antioxidant silymarin and skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

A unifying mechanism in the initiation of cancer and other diseases by catechol quinones

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Effect of silibinin on the growth and progression of primary lung tumors in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Enhancement of mammary carcinogenesis in two rodent models by silymarin dietary supplements

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Pharmacology of Silymarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

Radioprotective effect of silymarin against radiation induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735407301566

21 January 2018

Identifiers

DOI

10.1177/1534735407301566

1 reference

16 August 2017

1 reference

PubMed ID

17548795